Genmab (GMAB) said Monday new cohort data from its phase 1/2 trial of rinatabart sesutecan to treat patients with advanced endometrial cancer showcased "encouraging" anti-tumor activity and a 47.1% confirmed objective response rate at a dosage of 120 milligrams per square meter, every three weeks.
Participants who received the 100 milligrams per square meter dosage recorded a 50% confirmed objective response rate after a median follow-up of 7.7 months and two complete responses, according to the biotechnology company.
The median duration of response was not reached for both dosage levels, according to Genmab.
Common adverse events included diarrhea, dyspnea, headache, nausea, and urinary tract infection. Hematologic adverse events were managed without significant dose reduction, the company said.
The trial data were presented at the 2025 American Society of Clinical Oncology meeting in Chicago, Illinois.
Shares were up 4.2% in recent trading.
Price: 21.84, Change: +0.89, Percent Change: +4.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.